WO2013019145A2 - Produit biologiquement actif destiné à s'utiliser en médecine vétérinaire et en élevage, procédé de sa production et procédés d'amélioration de la survie, de stimulation de la croissance, d'immunostimulation et d'augmentation de la résistance non spécifique générale de l'organisme d'animaux d'élevage - Google Patents

Produit biologiquement actif destiné à s'utiliser en médecine vétérinaire et en élevage, procédé de sa production et procédés d'amélioration de la survie, de stimulation de la croissance, d'immunostimulation et d'augmentation de la résistance non spécifique générale de l'organisme d'animaux d'élevage Download PDF

Info

Publication number
WO2013019145A2
WO2013019145A2 PCT/RU2012/000578 RU2012000578W WO2013019145A2 WO 2013019145 A2 WO2013019145 A2 WO 2013019145A2 RU 2012000578 W RU2012000578 W RU 2012000578W WO 2013019145 A2 WO2013019145 A2 WO 2013019145A2
Authority
WO
WIPO (PCT)
Prior art keywords
biologically active
active product
product according
obtaining
larvae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/RU2012/000578
Other languages
English (en)
Russian (ru)
Other versions
WO2013019145A3 (fr
Inventor
Елена Александровна МОРЕНКО
Александр Викторович ПАЩЕНКО
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2013019145A2 publication Critical patent/WO2013019145A2/fr
Publication of WO2013019145A3 publication Critical patent/WO2013019145A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Definitions

  • Bioly active product for use in veterinary medicine and animal husbandry a method for its production and methods for increasing survival, growth stimulation, immunostimulation and increasing the general nonspecific resistance of an organism
  • the invention relates to the field of veterinary medicine, animal husbandry and zootechnology, namely, to a biologically active product based on components of natural origin, intended for use in veterinary medicine and animal husbandry, having immunostimulating, immunomodulating, growth-promoting, stimulating the general nonspecific resistance of the body action, and also to a method for preparing said biologically active product and to methods for increasing survival and growth stimulation in young rural farm animals and immunostimulation and enhance overall
  • nonspecific resistance of the organism of farm animals including intramuscular or subcutaneous administration of a biologically active product in accordance with the invention to said animals.
  • immunostimulants the use of such drugs in veterinary medicine allows increasing the body's defenses of animals, which, in turn, leads to an increase in the immune response during vaccinations (vaccines are more effective) and an increase in the activity of antibiotics and other antimicrobial agents.
  • the specified tool is administered to a sick animal intramuscularly or subcutaneously at a rate of 0.02-0.05 ml / kg body weight, preferably in the L L portion of the dose to the left and right of the spinal column in the dorsal muscles of the lower back, or subcutaneously on the right and left sides of the neck or 1/5 of the dose in six places around the focus of the pathology, or combined 3/8 of the dose in the muscles of the lower back to the right and left of the spinal column and 1/3 of the dose in six places around the pathological focus, once or several times with an interval of 5-7 days.
  • this agent contains formalin - an aqueous solution of formaldehyde, for which it has been repeatedly shown in the literature
  • RU "Stavropol State Agrarian University” (RU)) disclosed a method of preparing an immune modulator, comprising cooling selected fertilized uninfected eggs at a temperature of 2-4 ° C for up to 7 days,
  • the target product characterized in that the egg mass is diluted with saline in a ratio of 1: 5, then heat treatment is carried out in a water bath at a temperature of 70-8C for 1 hour and before preservation, the target product is cooled in a bactericidal chamber under an ultraviolet lamp for 30-40 minutes.
  • preservative - 0.3 g (0.3 wt.%); said agent is administered subcutaneously or
  • Lutsuk S.N. (RU), Belyaev V.A. (RU), Salushcheva M.S. (RU), Ruchiy O.S. (RU), Safonovskaya E.V.
  • a method for preparing a preparation for stimulating the organism of animals from drones larvae comprising collecting drones larvae, homogenizing them with the addition of a stabilizing medium, characterized in that drones are frozen before homogenization at a temperature of -4 ° ⁇ - 5 ° ⁇ for 12-14 hours, then thawed for 3-5 minutes to + 18 ° C, while a stabilizing medium using a 5% glucose solution in a ratio of 1:10, with the addition of a 5% solution of chloroform or 2% salicylic acid, followed by minutes sublimation, the sublimation is carried out in a vacuum chamber at a temperature of heating the shelves and + 30 ° C - + 45 ° C, wherein when the temperature of the drug + 20 ° C - + 22 ° C shelf temperature was lowered to + 25 ° C and produce
  • the preparation obtained in accordance with RU 2258522 C1 may contain residual amounts of solvent — chloroform, which, as has been repeatedly shown in the literature, also has carcinogenic, mutagenic, embryotoxic, and teratogenic properties, and can also lead to miscarriages in pregnant female domestic (agricultural ) animals; in addition, the preparation obtained by the method in accordance with RU 2258522 C1 is characterized by a limited spectrum of application and low biological activity.
  • EP 0 818 202 A1 also discloses a pharmaceutical composition containing from 0.5% to 5% of a product (preparation) obtained by the above method together with a pharmaceutically acceptable solvent (up to 100%).
  • the concentrate of nutrient and biologically active components containing drone homogenate brood, or sperm homogenate, and / or caviar of gray sea urchins, or ascidia caviar, and / or ascidium sperm, or milk and / or fish roe, or rooster sperm, or homogenate of bird embryos and / or components of bird eggs, or whole colostrum mammals, or homogenate of scallop gonad, or homogenate of male and / or female mussel gonads, or culture medium removed from human and / or animal leukocyte cell culture, undergoing logarithmic growth and containing growth factors and metabolic products of these leukocyte cells, Lebanon total osmotic activity not less than 2000
  • RO 118 115 B also discloses a method for producing a biologically active product, including collecting eggs and pupae of unpaired silkworms (Latin name (lat.) Lymantria dispar), Colorado potato beetle larvae (lat. Leptinotarsa decemlineata) and adult western May beetle (lat.
  • Melolontha melolontha their sterilization, grinding in an electric mill at a speed of 2500-5000 rpm (until a homogeneous homogeneous mass of light gray color is obtained), filtering the specified mass through a woven filter with a hole diameter (pore) of 200 to 250 microns, isolating residues (f iltrate?), filtration using a vacuum filter (up to obtaining a light gray suspension), lyophilization and spraying to obtain a lyophilisate powder, and the use of the specified biologically active substance (biologically active product) for the preparation of a medicinal product (medication) for the treatment of infectious liver disease.
  • a biologically active substance biologically active product
  • the biologically active product in accordance with RO 118115 B is intended only for the treatment of infectious diseases of the liver; the possibility of using this product as an immunostimulating, immunomodulating and
  • a growth-promoting veterinary agent is not indicated.
  • RF patent RU 2157232 C1 “The drug and method for its preparation” (publ. 10.10.2000, inventors and patent holders - F. Luknitsky (RU), Potapov AM (RU), Valov G.Yu. (RU)) discloses the drug having immunostimulating and adaptogenic action; the specified preparation contains a water-alcohol extract of the active principle of plant origin (active components of wheat germ), with the ratio of ingredients in the specified preparation, wt.%:
  • Patent RU 2157232 C1 also discloses a method for producing said
  • immunostimulating and adaptogenic preparation based on wheat germ including treatment of the germ with a solvent (30-50% aqueous solution ethyl alcohol) at room temperature for at least 20 minutes, separating the extract (by decantation, filtration or a combination of decantation and filtration), heat treatment (heating the extract at a temperature of + 60 ° C - + 70 ° C for at least 40 minutes ), isolation of the active principle and purification of the final product (filtration through activated carbon).
  • the final product obtained by the method in accordance with patent RU 2157232 C1 contains large amounts of ethyl alcohol, which makes its course veterinary use undesirable for the treatment (treatment) of large
  • preparation of a biogenic stimulator including 50% of the biologically active mass from drones larvae, 49.7% sodium chloride solution and 0.3% preservative, characterized in that for the preparation of the preparation, cells with live healthy drone brood aged 18-22 days are kept in the refrigerator at at a temperature of 3-4 ° C for 5-6 days, then the brood honeycombs are opened and drones of the same size, light gray in color, are selected, after which the drones are crushed in a sterile laboratory mill, diluted with a sterile solution of sodium chloride Ia with a concentration of 0.9% in the ratio 1: 1 and autoclaved at
  • the disadvantage of the method disclosed in RU 2395289 C1 is the need for a long (within 1 hour) autoclaving of the drug at high temperature (+ 120 ° C) and a pressure 1.5 times higher than atmospheric; specified conditions
  • Evglevskaya E.P. (RU), Kolomiytsev SM. (RU), Pankova SJ. (RU), Ryzhkova G.F. (RU), Rusakova N.M. (RU)).
  • the method proposed in accordance with RU 2414919 C1 includes collecting drones larvae from 5 to 14 days old, freezing them for 3-5 minutes at temperature -4 - -5 ° C for 12-14 hours, followed by thawing to + 18 ° C and homogenization, followed by the addition of a stabilizing medium,
  • acetylsalicylic acid and sublimation are carried out in a vacuum chamber at a temperature of shelf heating to + 30 ° ⁇ - + 45 ° ⁇ , while when the temperature reaches + 20 ° ⁇ - + 22 ° ⁇ , the temperature of the shelves is reduced to + 25 ° ⁇
  • diacetophenonyl selenide is used as the organo-selenium compound
  • a drying medium is used as a stabilizing medium — a sucrose-gelatin mixture comprising 10% sucrose and 5% gelatin in a ratio of homogenate and drying medium 1:10 , etc drones are taken from 5 to 14 days old, homogenization is carried out for 3-5 minutes, and diacetophenonyl selenide is added after homogenization in an amount of 3.5-4 mg per 100 ml of homogenate, then homogenate and acetylsalicylic acid in an amount of 0.2% to the volume,
  • FIG. 1 Live weight of piglets (from birth to 6 months) when using the drug (in comparison with the control group)
  • FIG. 2 Preservation (survival) of piglets when using the drug (%, compared with the control group)
  • FIG. 3 Live weight of calves from birth to up to 6 months when using the drug (in comparison with the control group)
  • FIG. 4 Preservation (survival) of calves when using the drug,% (compared with the control group)
  • FIG. 5 Indicators of immunity (immunogram) of animals of the experimental and control groups.
  • the biologically active product in accordance with the invention contains a full range of biologically active substances from animal and vegetable tissues
  • immunostimulants and growth stimulants used in veterinary medicine and animal husbandry can be successfully used in all types of farm animals of various sex and age groups - to increase survival and growth of young animals, to smooth out complications after vaccination, for the complex treatment of infectious and protozoal diseases in farm animals, and .tp
  • seeds or seedlings of plants of the cereal family preferably seedlings aged 5-7 days of plants such as rye (Secale cereale), seed oats (Avea sativa), ordinary barley (Hordeum vulgare), common wheat (Triticum vulgare) and corn (Zea mays)), fertilized fish eggs (preferably fish that are allowed to
  • carp preferably carp (Cyprinus carpio), carp (Cyprinus carpio), silver carp
  • pasteurization is carried out in a water bath at a temperature of +56 e C to +70 d C for 1.5-3 hours; preferably, 1-5% mannitol, or 1-5% sucrose, or 1-5% glucose, or 1-5% lactose, or 1-5% trehalose is used as the cryoprotectant in the most preferred (however, not limiting the scope of claims in accordance with the present invention) embodiment, the composition of the biologically active product contains:
  • the drug is diluted with 0.9% NaCI solution or sterile pyrogen-free distilled water for injection.
  • the invention may additionally contain acceptable in veterinary medicine
  • fillers, excipients, preservatives in particular, as a preservative within of the present invention can be used nipagin in the form of 0.01-0D% solution) and other auxiliary components, and is suitable for intramuscular or
  • Seeds and seedlings (5-7 days old) of seed rye (Latin Secale cereale), or seed oats (Latin Avea sativa), or ordinary barley (Latin Hordeum vulgare), or ordinary wheat (Latin Triticum vulgare), or corn (lat. Zea mays), in
  • Muscidae larvae of cocoon moths (Lasiocampidae), larvae of mosquito-jerks (Chironomidae), larvae of tubuloids (Tubificidae), larvae 20 g squeak mosquitoes (Culicidae) and bee larvae (Apidae), and (4) fertilized bird eggs selected from fertilized chicken order eggs (Gall iformes),
  • fertilized eggs of birds of the order Anatidae or fertilized eggs of birds of the order Anseriformes were incubated (in vivo or in incubator devices, at a temperature of + 37.3 ° C - + 37.5 ° C, for 5-7 days), in an amount of 25 g, then cooled to a temperature of + 8 ° C and homogenized using an ultrasonic homogenizer or high pressure homogenizer.
  • the resulting homogenate was diluted with 0.9% NaCI solution (saline), in the ratio "homogenate: 0.9% NaCI", equal to 1: 3, then placed (for pasteurization) for 2 hours in a water bath at a temperature of + 58 ° FROM; the resulting product was filtered under sterile conditions using cloth filters
  • the shelf life of the product obtained in accordance with Example 1 was 6-8 months (at temperatures from + 5 ° C to + 7 ° C).
  • the invention was studied on two types of farm animals - domestic pigs (Sus scrofa domestica) and domestic cows (Bos taurus taurus).
  • the preparation obtained in accordance with example 1 was diluted with distilled water for injection or 0.9% sodium chloride solution and was administered to animals of experimental groups (calves and piglets at the age of 2, 5 and 8 days) subcutaneously or intramuscularly, to the right and left of the spinal column in the dorsal muscle, the right and left neck, thigh, breast muscle under the front limb or other body parts of a a portion of the dose rate of 0.05 to 0.1 ml / kg body weight; animals of the control group were injected
  • the parameters of the immune system including the number (% of the total number of lymphocytes) of B-lymphocytes, T-lymphocytes, as well as the level of circulating immune complexes (CEC), and -globulins, ⁇ -globulins and ⁇ -globulins in blood plasma.
  • Table 1 The results of the use of the drug in young farm animals are shown in Table 1 and in FIG. 1-5.
  • Table 1 The values of immunity indicators (immunogram) of animals of the experimental and control groups (calves aged 4-6 months).
  • the level of T-lymphocytes in the experimental group was 54.27% higher than in the control group
  • the level of CEC (circulating immune complexes) in the experimental group was 51.22% higher than in the control group
  • the level of alpha globulins in the experimental group was 60.61% higher than in the control group
  • the level of beta-globulins in the experimental group was 38.64% higher than in the control group
  • the level of gamma globulins in the experimental group was 87.32% higher than in the control group of animals.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Insects & Arthropods (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne le domaine de la médecine vétérinaire et de l'élevage et concerne notamment un procédé de production d'un produit biologiquement actif d'origine naturelle destiné à s'utiliser en médecine vétérinaire et en élevage qui possède des effets immunostimulant, immunomodulateur, stimulant la croissance, augmentant la résistance générale non spécifique de l'organisme et une action favorisant l'adaptation; il comprend des graines ou des pousses de plantes graminées, des oeufs de poisson fécondés, des larves d'insectes et des oeufs d'oiseaux fécondés à des stades de développement précoces, un produit biologiquement actif produit par ce procédé et des procédés pour augmenter la survie et améliorer la croissance de jeunes animaux d'élevage (a) et permettre l'immunostimulation et l'augmentation de la résistance générale non spécifique de l'organisme d'animaux d'élevage (b), y compris l'administration intramusculaire ou sous-cutanée à ces animaux du produit biologiquement actif selon invention aux animaux élevage (en utilisant un excipient acceptable pour l'usage vétérinaire). Le produit biologiquement actif de la présente invention possède des propriétés prononcées de stimulation de la croissance et des défenses immunitaires ainsi qu'une action immunostimulante; sa production est peu couteuse et il ne comprend pas de solvants toxiques (cancérigènes).
PCT/RU2012/000578 2011-08-02 2012-07-18 Produit biologiquement actif destiné à s'utiliser en médecine vétérinaire et en élevage, procédé de sa production et procédés d'amélioration de la survie, de stimulation de la croissance, d'immunostimulation et d'augmentation de la résistance non spécifique générale de l'organisme d'animaux d'élevage Ceased WO2013019145A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2011132483 2011-08-02
RU2011132483/15A RU2011132483A (ru) 2011-08-02 2011-08-02 Биологически активный продукт для применения в ветеринарии и животноводстве, способ его получения и способы повышения выживаемости, стимуляции роста, иммуностимуляции и повышения общей неспецифической резистентности организма сельскохозяйственных животных

Publications (2)

Publication Number Publication Date
WO2013019145A2 true WO2013019145A2 (fr) 2013-02-07
WO2013019145A3 WO2013019145A3 (fr) 2013-04-11

Family

ID=47629827

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2012/000578 Ceased WO2013019145A2 (fr) 2011-08-02 2012-07-18 Produit biologiquement actif destiné à s'utiliser en médecine vétérinaire et en élevage, procédé de sa production et procédés d'amélioration de la survie, de stimulation de la croissance, d'immunostimulation et d'augmentation de la résistance non spécifique générale de l'organisme d'animaux d'élevage

Country Status (2)

Country Link
RU (1) RU2011132483A (fr)
WO (1) WO2013019145A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2557527C1 (ru) * 2014-07-10 2015-07-20 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский ветеринарный институт Нечернозёмной зоны Российской Федерации" (ФГБНУ "НИВИ НЗ России") Способ коррекции иммунобиохимического статуса у коров в предродовом и послеродовом периодах

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO74872A2 (fr) * 1980-01-21 1983-11-01 Cooperativa Agricola De Productie,Ro Procede pour l'obtention d'un produit apicole biologiquement actif
RU2009644C1 (ru) * 1991-10-21 1994-03-30 Анатолий Константинович Лихотин Корм для животных
RU2082169C1 (ru) * 1992-01-31 1997-06-20 Александр Борисович Полетаев Способ биостимулирования организма животного
RU2257907C2 (ru) * 2003-09-30 2005-08-10 Сибирский институт физиологии и биохимии растений Сибирского отделения Российской академии наук Способ получения биологически активного вещества для регуляции энергетического баланса
AR048098A1 (es) * 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
RU2287960C2 (ru) * 2004-12-15 2006-11-27 Вячеслав Васильевич Сова Способ получения комплекса липидов и витаминов из икры рыб
DE102005025283A1 (de) * 2005-06-02 2006-12-07 Bayer Healthcare Ag Stabiler Wirkstoffkomplex von Salzen der o-Acetylsalicylsäure mit basischen Aminosäuren und Glycin
RU2416394C1 (ru) * 2010-01-25 2011-04-20 Пшеничников Виталий Георгиевич Фармацевтическая композиция в виде спрея для лечения раневых поверхностей

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2557527C1 (ru) * 2014-07-10 2015-07-20 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский ветеринарный институт Нечернозёмной зоны Российской Федерации" (ФГБНУ "НИВИ НЗ России") Способ коррекции иммунобиохимического статуса у коров в предродовом и послеродовом периодах

Also Published As

Publication number Publication date
RU2011132483A (ru) 2013-02-10
WO2013019145A3 (fr) 2013-04-11

Similar Documents

Publication Publication Date Title
US11065287B2 (en) Methods of modulating immune and inflammatory responses via administration of an algal biomass
CN101343317B (zh) 脑肽及其制备方法及其用途
RU2493873C1 (ru) Инъекционный препарат для повышения спермопродукции у производителей сельскохозяйственных животных и петухов и способ его применения
CN106577536A (zh) 一种防草鱼肠炎病的养殖方法
RU2395289C1 (ru) Способ изготовления биогенного стимулятора из личинок трутневого расплода пчел
RU2706689C1 (ru) Способ лечения мастита у коров
KR20100027743A (ko) 봉독 사료와 가축
WO2013019145A2 (fr) Produit biologiquement actif destiné à s'utiliser en médecine vétérinaire et en élevage, procédé de sa production et procédés d'amélioration de la survie, de stimulation de la croissance, d'immunostimulation et d'augmentation de la résistance non spécifique générale de l'organisme d'animaux d'élevage
RU2377930C1 (ru) Способ получения биологически активной добавки (варианты)
RU2563358C1 (ru) Способ повышения репродуктивной функции коров и жизнеспособности новорожденных телят
CN104208678B (zh) 一种兽用抗病毒组合物、冻干粉、制备方法及应用
Alcalá-Escamilla et al. Main bioactive components and therapeutic properties of bee (Apis mellifera L.) venom. Review
RU2414227C1 (ru) Иммуномодулятор для выращивания бройлеров и способ его применения
Borum Apitherapy and applications in veterinary medicine
CN105368787A (zh) 一种鸡新城疫、禽流感同胚培养的方法
WO2023062207A1 (fr) Compositions thérapeutiques et préventives
RU2198671C2 (ru) Способ получения препарата на основе экстракта плаценты коров
RU2222337C1 (ru) Способ получения иммуностимулятора
RU2561863C1 (ru) Способ изготовления биологического стимулятора
JPH0967265A (ja) 魚類病原ウイルスに対する抗ウイルス剤
ES2259933B1 (es) Procedimiento de obtencion de un extracto rico en saponinas de killay y jaboncillo combinadas con romero, salvia y tomillo, extracto obtenido y su uso en un compuesto medicinal para el tratamiento de vacunos y equinos.
RU2363481C1 (ru) Способ производства пантогематогена
RU2774843C1 (ru) Способ получения кормовой добавки для выращивания цыплят бройлеров
RU2304398C2 (ru) Способ повышения продуктивности птицы
RU2808576C1 (ru) Способ лечения пчелосемей, пораженных ассоциативной инфекцией варроозом, американским и европейским гнильцом

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12820234

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12820234

Country of ref document: EP

Kind code of ref document: A2